Fig. 3. Duration of treatment and time to progression (n = 22).

Duration and time to progression are defined as the interval from the date of enrolment to date of either progression or date of last disease assessment. *This patient was replaced due to being enrolled under DL3 but treated at DL2. ^#This patient was replaced due to not having received 75% of cycle 1 dosing. ^βThis patient had tumour shrinkage by 28%.